We provide you with 20 years of free, institutional-grade data for ALRN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ALRN. Explore the full financial landscape of ALRN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about ALRN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Aileron Therapeutics, Inc(NASDAQ:ALRN) 
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the trea...
Website: http://www.aileronrx.com
Founded: 2001
Full Time Employees: 13
Sector: Healthcare
Industry: Biotechnology